﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Pharmaceutical Sciences</JournalTitle>
      <Issn>1735-403X</Issn>
      <Volume>27</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2021</Year>
        <Month>12</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The Combination of Berberine and Methotrexate Enhances Anti-Cancer Effects in Hela Cancer Cell Line: A Morphological Study</ArticleTitle>
    <FirstPage>536</FirstPage>
    <LastPage>542</LastPage>
    <ELocationID EIdType="doi">10.34172/PS.2021.12</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Majidzadeh</LastName>
      </Author>
      <Author>
        <FirstName>Mostafa</FirstName>
        <LastName>Araj-Khodaei</LastName>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Ghaffari</LastName>
      </Author>
      <Author>
        <FirstName>Amir</FirstName>
        <LastName>Jafari</LastName>
      </Author>
      <Author>
        <FirstName>Dariush</FirstName>
        <LastName>Shanehbandi</LastName>
      </Author>
      <Author>
        <FirstName>Mohammadali</FirstName>
        <LastName>Torbati</LastName>
      </Author>
      <Author>
        <FirstName>Jafar</FirstName>
        <LastName>Ezzati Nazhad Dolatabadi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-7434-5541</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/PS.2021.12</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>01</Month>
        <Day>26</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>02</Month>
        <Day>27</Day>
      </PubDate>
    </History>
    <Abstract>Background: Co-administration of two or several either chemotherapeutic agents or conventional drugs as a combination treatment is the most effective method to increase therapeutic efficiency. Additive or synergistic influence are two mechanisms by which combination therapy causes a rise in optimal cancer therapy compared to a single treatment. Methods: Colorimetric assay was carried out to estimate the cytotoxicity of the combined system, followed by apoptosis assay to calculate the number of apoptotic cells. Both 4′,6-diamidino-2-phenylindole (DAPI) staining and DNA ladder were complemented tests to illuminate morphological changes and DNA fracturing on HeLa cancer cells. Results: We revealed that the combination of berberine (BER) and methotrexate (MTX) could inhibit the growth of HeLa cancer cells noticeably. Nevertheless, single BER and MTX were not as effective as a combined system to reduce cell viability at the same dose. Regarding the apoptosis induction and change in morphology of cancer cells’ nucleus, co-treatment of BERand MTX was more effective. The result was complemented with flow cytometry, DAPI staining and DNA ladder, which showed that BER+MTX depicted more anti-cancer effects. Conclusion: The combination therapy of HeLa cancer cells with BER and MTX showed high inhibition effect compared to other treated groups.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">HeLa cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methotrexate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Berberine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Herbal Medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear Morphology</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>